Reagents and methods for modulating Dkk-mediated interactions

Details for Australian Patent Application No. 2002342734 (hide)

Owner Wyeth Oscient Pharmaceuticals Corporation

Inventors Allen, Kristina; Anisowicz, Anthony; Damagnez, Veronique; Yaworsky, Paul J.; Robinson, John Allen; Bhat, Bheem M.

Agent Blake Dawson Waldron Patent Services

Pub. Number AU-B-2002342734

PCT Number PCT/US02/15982

PCT Pub. Number WO2002/092015

Priority 60/353,058 01.02.02 US; 60/291,311 17.05.01 US; 60/361,293 04.03.02 US

Filing date 17 May 2002

Wipo publication date 25 November 2002

Acceptance publication date 26 July 2007

International Classifications

A01K 67/027 (2006.01) Rearing or breeding animals, not otherwise provided for - New breeds of vertebrates

A61K 31/7105 (2006.01) - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 3/14 (2006.01) Drugs for disorders of the metabolism

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 19/00 (2006.01) Drugs for skeletal disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C07K 14/51 (2006.01) Peptides having more than 20 amino acids

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12N 15/85 (2006.01) Mutation or genetic engineering - for animal cells

C12Q 1/02 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving viable micro-organisms

G01N 33/15 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Medicinal preparations

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

G01N 33/92 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving lipids, e.g. cholesterol

Event Publications

27 February 2003 Complete Application Filed

  Priority application(s): 60/353,058 01.02.02 US; 60/291,311 17.05.01 US; 60/361,293 04.03.02 US

1 May 2003 Application Open to Public Inspection

  Published as AU-B-2002342734

17 August 2006 Assignment before Grant

  Wyeth; Genome Therapeutics Corporation The application has been assigned to Wyeth; Oscient Pharmaceuticals Corporation 2003

26 July 2007 Application Accepted

  Published as AU-B-2002342734

22 November 2007 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002342735-Quinoline derivatives as neuropeptide Y antagonists

2002342733-BLIND FOR A ROUND WINDOW